In-vitro Diagnostics Market to be Worth $130.1 Billion by 2030
o
|
|
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=4858
According to this latest publication from
Meticulous Research®, the global in vitro diagnostics market is expected to register
a CAGR of 4.6% from 2023 to reach $130.1 billion by 2030. The growth of the
global in vitro diagnostics market is mainly attributed to the rising
prevalence of chronic diseases coupled with the increasing geriatric
population, rising prevalence of acute and chronic infectious diseases,
increasing funding for research activities, growing awareness regarding early
disease diagnosis, growing demand for point-of-care (POC) diagnostics and
rapid diagnosis, rising healthcare expenditure, and increasing funding for
research activities. Further, emerging economies, increasing inclination
toward personalized medicine, and advancements in genomics & proteomics
offer significant growth opportunities for the players operating in this
market. However, stringent technical requirements and regulatory processes for
high/moderate-complexity tests and variance in test results observed in rapid IVD
tests are expected to hinder the growth of this market. The evolving
regulatory landscape poses a challenge for the global IVD market.
Key Players
The key players operating in the global in
vitro diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and
Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.),
Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina,
Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical
Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher
Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC
(Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.),
and DiaSorin S.p.A. (Italy).
Global In Vitro Diagnostics
Market: Future Outlook
The global in vitro diagnostics market is
segmented by offering [{reagents & kits, systems, and software &
services), technology {molecular diagnostics (polymerase chain reaction (PCR),
hybridization, isothermal nucleic acid amplification technology, DNA
sequencing & next-generation sequencing, microarray, mass spectrometry,
other molecular diagnostic technologies) Point-of-Care (PoC) diagnostics
(lateral flow assays/rapid tests, PoC molecular diagnostics, other
PoC products), immunoassay/immunochemistry (enzyme-linked immunosorbent assays
(ELISA), enzyme-linked immunospot assays, western blotting, radioimmunoassay),
biochemistry/clinical chemistry (metabolic panels, electrolyte panels, liver
panels, lipid profiles, renal profiles, thyroid function panels), whole blood
glucose monitoring, microbiology, hematology, coagulation/hemostasis,
urinalysis, and other IVD technologies}, application {infectious diseases
(COVID-19 testing, sexually transmitted diseases (STD) testing,
healthcare-associated infections (HAIs), hepatitis, HIV, tropical diseases,
influenza, respiratory infections (excluding influenza), other infectious
diseases), oncology, diabetes, cardiology, nephrology, autoimmune disorders,
and other applications), diagnostic approach {laboratory testing,
OTC/self-testing, and Point-of-Care testing}, end user {diagnostic
laboratories, hospitals & clinics, home healthcare, and other end users}],
and geography. The study also evaluates industry competitors and analyzes
their market share at the global and regional levels.
Based on offering, the reagents &
kits segment is expected to account for the largest share of the in vitro
diagnostics market in 2023. The large market share of this segment is mainly
attributed to the frequent use of assays & kits in the detection of
various chronic diseases, the commercial availability of a diverse range of
reagents & consumables for various diseases diagnosis, the increase in the
volume of testing for infectious disease, especially after the COVID-19
pandemic, and the growing awareness about self-testing kits among the general
population.
Speak to analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=4858
Based on technology, in 2023, the
molecular diagnostics segment is expected to account for the largest share of
the in vitro diagnostics market. The large market share of the segment is
mainly attributed to the growing prevalence of infectious diseases and
diagnosing a disease by analyzing DNA or RNA or their proteins as well as the
development of automated instrument systems which provide accurate results
using PCR and other molecular technologies.
Based on application, in 2023, the
infectious diseases segment is expected to account for the largest share of
the in vitro diagnostics market. The large market share of this segment is
attributed to the rising prevalence of infectious diseases, government
initiatives to promote awareness and testing, and emerging outbreaks of
infectious diseases around the world.
Based on diagnostic
approach, the lab testing segment is expected to account for the
largest share of the in vitro diagnostics market in 2023. The large market
share of this segment is primarily attributed to its higher accuracy and
reliability, lower costs, availability of several IVD tests, and availability
of a quality assurance program.
Based on end user, in 2023, the
diagnostics laboratories segment is expected to account for the largest share
of the in vitro diagnostics market. The large market share of this segment is
primarily attributed to the rising laboratory automation, availability of
well-equipped systems, lack of skilled labor, growing prevalence of infectious
diseases, and rising government initiatives.
Geographic Review
This research report analyzes major
geographies and provides a comprehensive analysis of North America (U.S.,
Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, and the
Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea,
and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Rest of
Latin America), Middle East (Saudi Arabia and Rest of Middle East), and Africa
(South Africa and Rest of Africa).
Based on geography, North America is expected
to account for the largest share of the in vitro diagnostics market in 2023.
The large market share of North America is attributed to the rising prevalence
of chronic and infectious diseases, increasing awareness regarding early
disease diagnosis, growing adoption of advanced diagnostic products, and
increasing funding activities coupled with novel developments in diagnostic
technologies.
Quick buy: https://www.meticulousresearch.com/Checkout/87380450
Key questions answered in
the report-
· Which are
the high-growth market segments in terms of offering, technology, application,
diagnostic approach, end user, and geography?
· What was
the historical market for in vitro diagnosis across the globe?
· What are
the market forecasts and estimates for the period 2023–2030?
· What are
the major drivers, restraints, challenges, and opportunities in the global in
vitro diagnostics market?
· Who are
the major players in the global in vitro diagnostics market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment